South Korea developed both COVID-19 vaccines and treatments
Oh Yoo-kyung, director of the MFDS said in a briefing on the 29th, “We decided to grant SKYCovione’s item permission as a condition of submitting the final result report of the clinical trial.” SKYCovione is a gene recombination type COVID-19 vaccine, developed by SK Bioscience in cooperation with the University of Washington in the U.S.
SKYCovione will be used for the first and second basic vaccinations like Pfizer and AstraZeneca, which are currently in use. It was approved for the purpose of preventing COVID-19 in adults over the age of 18 and it is used for inoculation. In addition, it can be stored in a refrigerator between 2 to 8 degrees Celsius, so it can be used in places without ultra-low temperature distribution equipment.
Preventive effect of SKYCovione is more than AstraZeneca (AZ)’s “Vaxzevria.” When 0.5 mL is injected twice every four weeks to adults aged 18 or older, after 14 days, neutralizing antibodies that lower the risk of virus infection formed 2.93 times than AstraZeneca and the serum conversion rate was 10.76% higher than those who didn’t receive the vaccine (88.30%). Once additional booster shot efficacy and safety clinical trials are completed, they can be used for vaccinations of 3rd to 4th rounds or more in the future.
Director Oh said, “The existing vaccines have been developed for Wuhan strain. We should wait for SKYCovione’s clinical trial with the Omicron variant. SKYCovione was approved on the basis of data for basic vaccination, and the additional vaccination plan will be judged comprehensively in consultation with health authorities such as the Korea Centers for Disease Control and Prevention.”
<저작권자 ⓒ 먼데이타임스 무단전재 및 재배포 금지>
많이 본 기사